Under the agreement, both parties will thoroughly implement the national strategy for scientific self-reliance, while focusing on key technological challenges in pancreatic diseases, and jointly establishing major research projects that aim to achieve "zero-to-one" breakthroughs.

The parties will also implement the National Health Commission's guidelines on optimizing the layout of grassroots medical institutions, jointly establish projects for grassroots cooperation, and work to widely promote CAP's novel concepts, methods, technologies, and products to grassroots medical institutions nationwide.

Both parties will collaborate on public education programs that raise awareness of pancreatic diseases and foster societal engagement in prevention and treatment efforts.

Representing a groundbreaking initiative in pancreatic disease prevention and treatment, the strategic partnership can help CAP and Hengrui Pharma elevate China's healthcare capabilities in pancreatology, improve public health outcomes, and inject new momentum into the high-quality development of the field.